Sabrina McCrear

Social determinants of health can delay access to NGS, limiting targeted therapy use and survival outcomes in advanced cancers.

JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long COVID risk and symptom severity.

A study suggests vitamin D may reduce long COVID symptoms at 8 weeks, although larger trials are needed to confirm benefits and optimal timing, explains JoAnn E. Manson, MD, MPH, DrPH.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

A decade after the CDC opioid guidelines, Michael Lynch, MD, examines misapplication, fentanyl’s role, and evolving pain management strategies.

Experts discuss how CDC opioid guidelines reduced prescribing but led to misapplication, affecting patient care and access to pain treatment.

LLMs may improve pediatric clinical decision-making, but gaps in safety, accuracy, and pediatric-specific data remain.

Medicare Advantage enrollees with advanced cancer had higher hospice use than those with traditional Medicare, highlighting disparities in end-of-life care.

March marks the 10th anniversary of the CDC's opioid prescribing guidelines for patients with chronic pain, which were later updated to expand their scope.

Panelists at a Boston Regional Institute for Value-Based Medicine event examined trial diversity, integrated dispensing, and evolving oncology pathways.

Explore frequently asked questions on IPF therapies, including approved drugs, emerging treatments, and approaches to slow fibrosis.

Explore FAQs on AI in radiology, including malpractice risk, liability, and how juror perceptions shape legal outcomes when AI is involved.

Pulmonary expert Noah Greenspan, DPT, discusses long COVID, early pandemic uncertainty, and how vaccination may help reduce infection risk and severity.

A study explores how AI-assisted double-reading in radiology may influence malpractice risk and jury decisions in clinical care scenarios.

Noah Greenspan, DPT, discusses how oxygen therapy, detailed evaluation, and trial-and-error approaches may help manage long COVID symptoms.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

Michael Bernstein, MD, discusses how AI-assisted radiology workflows affect liability, automation bias, and patient safety in diagnostic imaging.

The 2026 V-BID Summit showcases strategies to make health care more affordable, equitable, and outcomes-driven.

A mock jury study suggests AI-assisted double reads may reduce perceived radiologist liability in malpractice cases.

A study of 46 million visits finds telemedicine remains above prepandemic levels, but older adults and minority groups are less likely to use virtual care.

Noah Greenspan, DPT explains challenges diagnosing long COVID and strategies like pacing, compression, and electrolytes to support recovery.

April Armstrong, MD, MPH, discusses choosing AD therapies, JAK inhibitor safety, response measures, and emerging treatments shaping the field.

The FDA approved kinase inhibitors, biologics, a pancreatic cancer device, GLP-1 updates, and a new ultrarare disease pathway in February 2026.

Experts examine evolving long COVID definitions, risk factors, diagnosis challenges, vaccine impact, and workforce effects.

Nurse understaffing linked to higher in-hospital mortality, 30-day readmissions, and longer stays.

Kevin Ma, PhD, discusses new data showing 2024–2025 COVID-19 vaccines reduced hospitalization and severe outcomes.

Over 15,000 NYC nurses ratified new contracts after a 41-day strike, securing staffing protections, salary increases, and safety reforms.

Phase 2 trial finds 5-day preoperative RT in high-risk STS shows comparable wound complication rates and acceptable toxicity.

Higher local recurrence growth rates and high-grade tumors were linked to increased disease-specific death after resection.

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants.